(WASHINGTON, D.C) — The Consumer Healthcare Products Association (CHPA) spoke today before a Food and Drug Administration Advisory Nonprescription Drugs Advisory Committee, during which the committee discussed data submitted by Galderma Laboratories, L.P. to support the supplemental new drug application for over-the-counter (OTC) marketing of adapalene gel 0.1%. The proposed OTC use is for the treatment of acne and to clear up acne pimples and acne blemishes.
CHPA Senior Vice President, Policy, and General Counsel & Secretary David Spangler spoke on behalf of CHPA, highlighting how the power of access through prescription-to-OTC switch benefits consumers and the healthcare system.
